The combination group presented a lower protein level of VEGF-A, compared to those treated with magnolol or regorafenib alone, in HCC cells in vitro and in vivo (Figure 1G,H and Figure 6I). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.